Where is Immuneage located?

Immuneage is headquartered in San Francisco, United States.

Who is the current CEO of Immuneage?

Sebastian Aguiar Brunemeier of Immuneage. They have also founded 4 companies.

How many employees does Immuneage have?

As of Jun 30, 2026, the latest employee count at Immuneage is 1.

Where does Immuneage rank among its competitors?

Immuneage ranks 305th amongst 480 active competitors, of which 160 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of Immuneage?

Immuneage's top competitors include BeiGene, Biogen and argenx. Among them, DBV Technologies secured the most recent funding round in April, 2025.

Immuneage - 2026 Company Profile, Team & Competitors

Company Details

Drug discovery platform for immune system rejuvenation by using hematopoietic stem cells. The company's products include IA-101, an oral small molecule immune booster targeting respiratory infections, IA-201, an immune rejuvenation cocktail for targeting chemotherapy recovery and bone marrow transplantation, and IA-301, an HSC expansion platform targeting bone marrow transplantation as well as other immune cell types like T cells.

Website: immuneage.bio
Email ID: *****@immuneage.bio

Key Metrics

Founded Year

2022

Location

San Francisco, United States

Stage

Funding Raised

Investors

Edward Lando

Ranked

305^th among 480 active competitors

Employee Count

1 as on Jun 30, 2026

Similar Companies

BeiGene & 559 more

View Immuneage's full profile

Immuneage is a funded company. Immuneage has 1 angel investor.

The founders of Immuneage is Sebastian Aguiar Brunemeier. Sebastian Aguiar Brunemeier is the CEO of Immuneage.

Here are the details of Immuneage's key team members:

Sebastian Aguiar Brunemeier: Founder & CEO of Immuneage and founder of 4 other companies, including LongGame, Longbiofellowship and Healthspan Capital. They serve on the board of 1 company.

View details of Immuneage's Founder profiles and Board Members

Immuneage's employee count trend

Immuneage has 1 employees as of Jun 26. Here is Immuneage's employee count trend over the years:

Uncover Immuneage's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immuneage include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Immuneage, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
8th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
9th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
305th	Immuneage 2022, San Francisco (United States), Funding Raised	Drug discovery platform for immune system rejuvenation by using hematopoietic stem cells	-	-	29/100